Appili Therapeutics Inc. Expected to Post FY2023 Earnings of ($0.08) Per Share (TSE:APL)
Appili Therapeutics Inc. Expected to Post FY2023 Earnings of ($0.08) Per Share (TSE:APL)
Appili Therapeutics Inc. (TSE:APL – Get Rating) – Analysts at Zacks Small Cap increased their FY2023 earnings per share (EPS) estimates for shares of Appili Therapeutics in a research note issued to investors on Tuesday, February 21st. Zacks Small Cap analyst D. Bautz now expects that the company will earn ($0.08) per share for the year, up from their previous forecast of ($0.09).
阿皮里治療公司（TSE：APL-獲得評級）— 扎克斯小型股的分析師在 2 月 21 日（星期二）向投資者發布的研究報告中增加了阿皮利治療藥物的 FY2023 每股收益（EPS）的估計。扎克斯小型股分析師 D.Bautz 現在預計，該公司將在今年的每股收入（0.08 美元），高於他們之前的預測（0.09 美元）。
Appili Therapeutics (TSE:APL – Get Rating) last posted its quarterly earnings results on Tuesday, February 14th. The company reported C($0.02) earnings per share for the quarter, hitting the consensus estimate of C($0.02). The business had revenue of C$0.01 million during the quarter.
阿皮里治療學（TE：APL-獲取評級）上次發布了其季度收益業績於 2 月 14 日（星期二）。該公司報告了本季度每股盈利 C（0.02 美元），達到 C（0.02 美元）的共識估計。該業務在本季度的收入為 0.01 百萬加元。
Appili Therapeutics Price Performance
阿皮里治療價格性能
Read More
閱讀更多
- Carvana Skidding On Revenue Decrease, Heavy Debt Burden
- What Are Consumer Staples Stocks?
- Is Rocky Brands Dividend A Good Fit For Your Portfolio?
- Beyond Meat Stock Is Not Beyond Hope
- Analysts Holding As Pfizer Waits On Two Phase 3 Studies
- 減少收入減少，沉重的債務負擔
- 什麼是必需消費股？
- Rocky 品牌股息是否適合您的投資組合？
- 超越肉湯不是超越希望
- 作為輝瑞公司等待兩個階段 3 研究的分析師
Receive News & Ratings for Appili Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Appili Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
每日接收阿皮里治療學的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收有關 Appili 治療及相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。